Caribou Biosciences Inc (CRBU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caribou Biosciences Inc (CRBU) has a cash flow conversion efficiency ratio of -0.170x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.82 Million) by net assets ($122.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Caribou Biosciences Inc's balance sheet to measure how much of total assets are equity-financed.
Caribou Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Caribou Biosciences Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Caribou Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caribou Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PIE Industrial Bhd
KLSE:7095
|
0.036x |
|
Sunty Development Co Ltd
TW:3266
|
-0.061x |
|
Lucky Cement Co
TW:1108
|
0.039x |
|
Chia Chang Co Ltd
TW:4942
|
0.031x |
|
JIUMAOJIU INTL HLDGS LTD
F:3YU
|
N/A |
|
Elanor Commercial Property Fund
AU:ECF
|
0.066x |
|
Goodbaby International Holdings Limited
F:GBH
|
0.041x |
|
Cho Kwang Leat
KO:004700
|
0.003x |
Annual Cash Flow Conversion Efficiency for Caribou Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Caribou Biosciences Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Caribou Biosciences Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $122.17 Million | $-110.99 Million | -0.908x | -66.28% |
| 2024-12-31 | $252.95 Million | $-138.20 Million | -0.546x | -115.75% |
| 2023-12-31 | $368.40 Million | $-93.29 Million | -0.253x | +16.24% |
| 2022-12-31 | $300.87 Million | $-90.97 Million | -0.302x | -260.58% |
| 2021-12-31 | $387.82 Million | $-32.52 Million | -0.084x | -105.92% |
| 2020-12-31 | $-23.44 Million | $-33.22 Million | 1.417x | +133.05% |
| 2019-12-31 | $7.46 Million | $-32.01 Million | -4.289x | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapse… Read more